Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Total Non-current Assets
All assets not expected to be converted to cash within one year.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets remains negative
Q1 FY2026 total non-current assets was $0, compared with $876 a year earlier.
Context
- Total non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 1.78K | -67.0% |
| FY2023 | 2023-12-31 | 5.39K | -40.1% |
| FY2022 | 2022-12-31 | 9K | -28.6% |
| FY2021 | 2021-12-31 | 12.62K | — |
Total Non-current Assets vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 9, against a peer median of -22.8%.
- Total non-current assets amounts to 0.0% of total assets for GLSI, versus a peer median of 6.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $91.17M USD | -48.5% | -22.5% | 48.9% | |
| Mar 2026 | $90.54M USD | -1.6% | +21.3% | 33.3% | |
| Mar 2026 | $22.72M USD | +7152.7% | +269.0% | 76.5% | |
| Mar 2026 | $6.76M USD | -23.3% | -4.1% | 5.6% | |
| Mar 2026 | $3.54M USD | +13.8% | +604.9% | 3.7% | |
| Mar 2026 | CA$674K CAD | -44.5% | -15.0% | 8.3% | |
| Mar 2026 | $326K USD | -48.6% | -47.6% | 0.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | $186K USD | -22.2% | +221.3% | 0.3% |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding GLSI) | — | -22.8% | +8.6% | 6.9% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.